<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04192916</url>
  </required_header>
  <id_info>
    <org_study_id>MPN-DOACs</org_study_id>
    <nct_id>NCT04192916</nct_id>
  </id_info>
  <brief_title>Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms</brief_title>
  <acronym>MPN-DOACs</acronym>
  <official_title>Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione per la Ricerca Ospedale Maggiore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione per la Ricerca Ospedale Maggiore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with myeloproliferative neoplasms (MPN) are predisposed to have an increased&#xD;
      thrombotic and hemorrhagic risk and, in this context, the use of newly approved direct oral&#xD;
      anticoagulants (DOACs) may have improved bleeding risk compared to warfarin use. However, the&#xD;
      published experience is very limited and does not allow any conclusion. In the cohort of&#xD;
      patients with MPN and venous thromboembolism (VTE) of European Leukemia-net, only 3.3% of&#xD;
      patients had been treated with DOACs. Similarly, in a recent publication of a series of 760&#xD;
      patients with single-center MPN, only 25 (3.3%) were treated with a DOAC (13 for atrial&#xD;
      fibrillation and 12 for thrombotic events).&#xD;
&#xD;
      While it is known that the risk of thrombotic recurrence and haemorrhagic event during&#xD;
      warfarin treatment is about 30% at 5 years from the first event, the actual risk of such&#xD;
      events in MPN patients is not known.&#xD;
&#xD;
      The aim of the present study is therefore to obtain information on patients with MPN treated&#xD;
      with DOAC for atrial fibrillation (AF) and VTE. This is an international multi-center&#xD;
      retrospective survey aimed at describing the efficacy / safety of DOAC in the prevention of:&#xD;
&#xD;
        -  cardioembolic stroke in patients with MPN with AF&#xD;
&#xD;
        -  recurrent thrombosis in patients with MPN with VTE&#xD;
&#xD;
        -  major bleeding in all patients with MPN.&#xD;
&#xD;
      The results will allow to design future prospective studies that evaluate the benefit / risk&#xD;
      profile of DOAC compared to warfarin in these pathologies characterized by high risk of&#xD;
      thrombosis and, in some subgroups, of bleeding.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of major thrombosis and bleeding</measure>
    <time_frame>At 5 year from the start of treatment with DOACs</time_frame>
    <description>Cumulative incidence of major arterial and venous thrombosis and major bleeding as defined by the International Society on Thrombosis and Haemostasis (ISTH)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">442</enrollment>
  <condition>Myeloproliferative Neoplasm</condition>
  <arm_group>
    <arm_group_label>MPN patients treated with DOACs</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOACs</intervention_name>
    <description>Direct Oral Anticoagulants</description>
    <arm_group_label>MPN patients treated with DOACs</arm_group_label>
    <other_name>Dabigatran</other_name>
    <other_name>Edoxaban</other_name>
    <other_name>Rivaroxaban</other_name>
    <other_name>Apixaban</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with MPN treated with any DOAC for AF or VTE&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of Philadelphia-negative MPN according to World Health Organization (WHO)&#xD;
             2008 and/or 2016 criteria until 31/12/2018;&#xD;
&#xD;
          -  diagnosis of atrial fibrillation (AF) and/or diagnosis of venous thromboembolism (VTE)&#xD;
             including thrombosis of deep veins of the limbs and the abdomen, cerebral and&#xD;
             splanchnic veins (hepatic, portal, mesenteric, and splenic veins) and pulmonary&#xD;
             embolism;&#xD;
&#xD;
          -  treatment with DOACs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Administration of DOAC for any medical reason other than AF and/or VTE (excluding&#xD;
        superficial vein thrombosis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mount Sinai New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre Toronto</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RWTH Aachen University</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia, Ospedale Borgo Roma</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST- Papa Giovanni XXIII - S.I.M.T.</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Careggi di Firenze</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST MONZA Ospedale San Gerardo Clinica Ematologica</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II di Napoli Divisione di Ematologia e Trapianti del Midollo</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico di Palermo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo S.C Ematologia</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli IRCCS UCSC Ematologia</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette- S.C. Ematologia</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo di Vicenza - U.O.C di Ematologia</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic, Hematology Department</name>
      <address>
        <city>Barcellona</city>
        <zip>08034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Efficacy and safety profile</keyword>
  <keyword>Direct oral anticoagulants</keyword>
  <keyword>Real world data</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

